諾輝健康(06606.HK)急漲35% 盈喜料全年毛利及收入大增
諾輝健康-B(06606.HK)發盈喜,料全年毛利及收入大增,該股今天突破50天線(25.9元)後,升幅擴大,最高見29.25元,現報28.3元,急漲35%,成交急增至980萬股(僅次於去年2月中旬首掛日成交量),涉資2.55億元。
諾輝健康上週五(14日)收市後發盈喜指,受惠於產品常衛清及噗噗管收入及毛利增長推動,預計2021年全年收入介乎2.05-2.17億人民幣(下同),按年增約1.9-2.1倍;料毛利達1.47-1.58億元,按年升逾2.9-3.2倍,毛利率料升至67.7%-77%,遠高於2020年同期約52.8%。(sz/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.